ERBB2 and breast cancer: Figure 2B shows that compared to healthy tissues, the expression of HIF1AN was decreased in Luminal, HER2 positive, and triple negative BC. Furthermore, the expression of HIF1AN was decreased as the tumor level increased. Notably, middle-stage and late-stage BC had much lower expression of HIF1AN than early-stage BC (Figure 2C). HIF1AN expression was significantly decreased in BC than in all phases of lymph node phase specimens (Figure 2D).